SK2442004A3 - Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure - Google Patents

Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure Download PDF

Info

Publication number
SK2442004A3
SK2442004A3 SK244-2004A SK2442004A SK2442004A3 SK 2442004 A3 SK2442004 A3 SK 2442004A3 SK 2442004 A SK2442004 A SK 2442004A SK 2442004 A3 SK2442004 A3 SK 2442004A3
Authority
SK
Slovakia
Prior art keywords
present
treatment
atomoxetine
dementia
schizophrenia
Prior art date
Application number
SK244-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SK2442004A3 publication Critical patent/SK2442004A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SK244-2004A 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure SK2442004A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (1)

Publication Number Publication Date
SK2442004A3 true SK2442004A3 (en) 2004-12-01

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
SK244-2004A SK2442004A3 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Country Status (26)

Country Link
US (1) US20050009925A1 (es)
EP (1) EP1458368B1 (es)
JP (1) JP2005517647A (es)
KR (1) KR20040066895A (es)
CN (1) CN1713900A (es)
AU (1) AU2002352625A1 (es)
BR (1) BR0213581A (es)
CA (1) CA2467802A1 (es)
CO (1) CO5590907A2 (es)
CZ (1) CZ2004709A3 (es)
DE (1) DE60223718T2 (es)
EA (1) EA200400793A1 (es)
EC (1) ECSP045145A (es)
ES (1) ES2295435T3 (es)
HR (1) HRPK20040528B3 (es)
HU (1) HUP0402619A3 (es)
IL (1) IL161989A0 (es)
MX (1) MXPA04005716A (es)
MY (1) MY136367A (es)
NO (1) NO20042904L (es)
NZ (1) NZ532065A (es)
PL (1) PL369311A1 (es)
SK (1) SK2442004A3 (es)
TW (1) TW200300672A (es)
WO (1) WO2003049724A1 (es)
ZA (1) ZA200404274B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1530476A1 (en) * 2002-08-14 2005-05-18 Pharmacia & Upjohn Company LLC Use of reboxetine for the treatment of hot flashes
US20060100290A1 (en) * 2003-07-28 2006-05-11 Dunaway Leslie J Treatment of allergic rhinitis and asthma
EP1660064A2 (en) * 2003-08-27 2006-05-31 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
BRPI0510453A (pt) * 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317730A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Treatment for menopausal and perimenopausal vasomotor symptons
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
WO2013051266A1 (ja) * 2011-10-03 2013-04-11 独立行政法人国立長寿医療研究センター タウ凝集阻害剤
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
PT1632234E (pt) * 1999-07-01 2007-07-09 Pharmacia & Upjohn Co Llc (s,s)-reboxetina para o tratamento da síndrome de fadiga crónica
GEP20043160B (en) * 1999-10-13 2004-01-26 Pfizer Products Inc Us Biaryl Ether Derivatives, Pharmaceutical Compositions Containing Them and Their Use as Monoamine Reuptake Inhibitors
AU2002243451A1 (en) * 2001-01-02 2002-07-16 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
CZ2004709A3 (cs) 2004-10-13
PL369311A1 (en) 2005-04-18
DE60223718T2 (de) 2008-10-30
CN1713900A (zh) 2005-12-28
EP1458368A1 (en) 2004-09-22
HRPK20040528B3 (en) 2006-03-31
MXPA04005716A (es) 2004-12-06
DE60223718D1 (de) 2008-01-03
ECSP045145A (es) 2004-07-23
WO2003049724A1 (en) 2003-06-19
NZ532065A (en) 2007-03-30
ES2295435T3 (es) 2008-04-16
US20050009925A1 (en) 2005-01-13
JP2005517647A (ja) 2005-06-16
HRP20040528A2 (en) 2004-10-31
KR20040066895A (ko) 2004-07-27
CO5590907A2 (es) 2005-12-30
IL161989A0 (en) 2005-11-20
AU2002352625A1 (en) 2003-06-23
EP1458368B1 (en) 2007-11-21
EA200400793A1 (ru) 2004-10-28
HUP0402619A2 (hu) 2005-03-29
ZA200404274B (en) 2005-09-13
HUP0402619A3 (en) 2008-04-28
TW200300672A (en) 2003-06-16
NO20042904L (no) 2004-09-07
MY136367A (en) 2008-09-30
CA2467802A1 (en) 2003-06-19
BR0213581A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
US9808455B2 (en) Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
JP2006515628A (ja) ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
KR20060011873A (ko) 비정형 항정신약과 ｇａｂａ 조절제, 항경련성 약물 또는 벤조다이아제핀의 치료 혼합물
SK2442004A3 (en) Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure
CA2332814C (en) Combination therapy for treatment of refractory depression
CZ2001677A3 (cs) Farmaceutický prostředek
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
AU4008899A (en) Combination therapy for treatment of bipolar disorders
US6960577B2 (en) Combination therapy for treatment of refractory depression
US20050119248A1 (en) Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
MXPA05013877A (es) Asociacion de antagonista o agonista inverso del receptor h3 de histamina con anti-psicotico o antidepresivo y su utilizacion para preparar medicamento que prevenie los efectos indeseables de medicamentos psicotropicos.
US7884096B2 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
SK5422003A3 (en) Treatment of anxiety disorders
SK14502000A3 (sk) Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
RU2238084C2 (ru) Композиции, содержащие ингибиторы обратного захвата допамина, и способы их применения
Doran The Dopamine Hypothesis Revisited
MXPA00011353A (es) Uso de olanzapida en combinación con fluoxetina para terapia de la depresión refractaria
CA2617420A1 (en) Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines

Legal Events

Date Code Title Description
FC9A Refused patent application